Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
SRSarepta Therapeutics, Inc. logo

Sarepta Therapeutics, Inc. (SRPT)

NASDAQ Global Select · Currency in USD
$17.73 ▼ -0.45 (-2.48%)
At close: Oct 23, 4:00 PM ET. Market closed.
$17.78 ▲ +0.05 (+0.28%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$18.18
Open
$17.94
Day's Range
$17.15 – $17.94
52 Week Range
$14.68 – $24.68
Volume
1,285,422
Avg. Volume
3,298,310
Market Cap
$1.87B
Beta (5Y Monthly)
0.21
PE Ratio (TTM)
--
EPS (TTM)
-$1.30
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$21.60

Profile: Sarepta Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
835
CEO
Michael E. Severino

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate $0.07 · Revenue est. $352.20M
DateEst.Actual
Aug 5, 2026$0.22-$0.05Miss
May 6, 2026$0.98$3.16Beat
Feb 25, 2026-$1.03-$3.58Miss
Nov 3, 2025-$0.73-$1.80Miss
Aug 6, 2025$0.83$2.02Beat
May 6, 2025-$0.87-$4.60Miss

Analyst view

Consensus price target
$21.60 ▲ +21.8%
Range $17.00 – $27.00
Rating: Buy
Buy 56% · Hold 33% · Sell 11%

Get free alerts on SRPT and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.